Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antiviral
Biotech
Merck pays $9.2B for owner of flu antiviral J&J rejected
Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.
James Waldron
Nov 14, 2025 8:25am
Gilead pumps up virology pipeline with drug transporter deal
Sep 29, 2025 10:35am
Enanta sees RSV drug fail phase 2b but finds positives
Sep 29, 2025 8:05am
Ascletis slashes funds for former core programs in obesity pivot
Mar 26, 2025 10:00am
Shionogi's RSV antiviral reduces viral load in ph. 2 adult trial
Jan 30, 2025 5:32am
AI drug discoverer's antiviral reduces COVID in mouse lungs
Jan 21, 2025 12:42am
